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Abstract In March 2011, the Acromegaly Consensus
Group met to revise and update the guidelines on the
diagnosis and treatment of acromegaly complications. The
meeting was sponsored by the Pituitary Society and the
European Neuroendocrinology Association and included
experts skilled in the management of acromegaly. Com-
plications considered included cardiovascular, endocrine
and metabolic, sleep apnea, bone diseases, and mortality.
Outcomes in selected, related clinical conditions were also
considered, and included pregnancy, familial acromegaly
and invasive macroadenomas. The need for a new disease
staging model was considered, and design of such a tool
was proposed.
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Introduction
Since 2000, several consensus documents have been pub-
lished on various aspects of acromegaly management [1–7].
In 2003 a consensus on the diagnosis and treatment of
acromegaly complications was published [3], and in March
2011, the Acromegaly Consensus Group that had produced
these documents met to revise and update guidelines on
acromegaly complications. The meeting was sponsored by
the Pituitary Society and the European Neuroendocrinology
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Association and included experts skilled in acromegaly
management.
Patients with acromegaly have a considerable burden of
complications and co-existing illnesses, and factors contrib-
uting to increased mortality in acromegaly include higher
prevalence of hypertension, hyperglycemia or diabetes, car-
diomyopathy and sleep apnea [8]. The diagnosis and man-
agement of complications of disease are therefore critical for
assuring a favorable long-term outcome for this chronic ill-
ness. Current comorbidity issues were discussed by the group
and recommendations made for updating the 2003 guidelines.
Recommendations were graded, based on the GRADE
system [9, 10], depending on the quality of evidence as
very low quality (VLQ; expert opinion with one or a small
number of small uncontrolled studies in support), low
quality (LQ; large series of small uncontrolled studies),
moderate quality (MQ; one or a small number of large
uncontrolled studies or meta-analyses), or high quality
(HQ; controlled studies or large series of large uncontrolled
studies with sufficiently long follow-up). Recommenda-
tions were classed as discretionary recommendations (DR)
if based on VLQ or LQ evidence, and as strong recom-
mendations (SR) if based on MQ and HQ evidence.
Cardiovascular complications
Hypertension is highly prevalent, occurring in more than
40 % of patients with acromegaly, and early diagnosis and
early aggressive treatment of elevated blood pressure is
important irrespective of which acromegaly treatment is
employed (HQ) [11–17]. Hypertension in patients with
acromegaly is usually mild and readily treated with anti-
hypertensive drugs (VLQ) [3]. The choice of treatment for
hypertension should be similar to that in non-acromegaly
patients (DR). The effect of different medical treatments
for acromegaly on hypertension is as yet unclear (LQ) [15,
18–21]. Sleep apnea, which is present in most patients with
acromegaly, exacerbates hypertension (LQ) [22].
Cardiomyopathy is present in most patients with acro-
megaly, and baseline echocardiogram is indicated. Arrhythmia
is rarely a significant clinical challenge in acromegaly (MQ)
[16, 23]. Treatment of acromegaly improves early and inter-
mediate stage myocardial hypertrophy and cardiac dysfunction
(HQ) [24–26]. Improvement depends on age, presence of
hypertension and duration of the disease (LQ). Recent data
(published after the consensus meeting) show that cabergoline
does not aggravate prevalence or incidence of valve regurgi-
tation and remodeling [27], which are increased in acromegaly
(MQ) [28, 29]. Furthermore, somatostatin receptor ligands
(SRLs) may cause asymptomatic bradycardia (LQ) [30].
Rigorous clinical outcome measures (and not only biochemi-
cal goals) should be addressed in research studies.
The following routine baseline assessments are therefore
required for patients with acromegaly: electrocardiogram
(ECG), echocardiogram, blood pressure measurement, and the
Epworth scale or sleep study for sleep apnea (SR) (Table 1).
These patients also require assessment of the peripheral arterial
system. Particularly in gigantism, there is a need for assessment
of vascular disease including peripheral venous disease (DR).
Endocrine and metabolic complications
Diabetes
Diabetes occurs more frequently in acromegaly patients
than in the general population and is an important predictive
factor for increased mortality in patients with acromegaly
Table 1 Assessment of acromegaly complications at diagnosis and
during long-term monitoring
Diagnosis During long-term follow-up
Blood pressure measurement Every 6 months or when change
of treatment (if hypertensive)
Echocardiography Annually
ECG Annually
Epworth scale or sleep study Annually
Echo Doppler of peripheral
arterial and venous system
Annually particularly in
gigantism
OGTT Fasting blood glucose every
6 months (particularly in
uncontrolled disease and during
SRL therapy); HbA1c every
6 months if diabetes present
Total testosterone, SHBG and
prolactin (males)
Annually (free testosterone when
doubts in interpretation of total
testosterone)
LH, FSH, 17b-estradiol and
prolactin (females)
Annually (or when pregnancy is
desired)
AcroQoL Annually
DEXA Every 2 years if patient with
osteopenia/osteoporosis
Thoracic and lumbar spine X-ray Every 2–3 years if osteoporosis
risk factors, kyphosis or
symptoms
Colonoscopy Every 10 years (more frequently
if IGF-I remains persistently
elevated or if abnormal
colonoscopy or family history
of colonic cancer)
Genetic screening for markers of
familial acromegaly (if
suspicion)
ECG electrocardiography, OGTT oral glucose tolerance test, SRL
somatostatin receptor ligand, HbA1c glycated hemoglobin, SHBG sex
hormone-binding globulin, LH luteinizing hormone, FSH follicle-
stimulating hormone, AcroQoL Acromegaly Quality of Life Ques-
tionnaire, DEXA dual-energy X-ray absorptiometry, IGF-I insulin-
like growth factor-I
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(HQ) [31, 32]. Treatment of diabetes should be the same in
patients with or without acromegaly (DR) [32]. Generally,
lowering of growth hormone (GH) levels improves glyce-
mic control and enhances insulin sensitivity (GH is a
powerful insulin antagonist), whatever mode of treatment is
used (MQ). An exacerbation of carbohydrate intolerance
may occur rarely in patients receiving SRLs (MQ) [32–34]
(but hyperglycemia occurs more frequently with pasireotide
than with other SRLs) [35] and pegvisomant may be con-
sidered for treatment of these patients (DR).
Hypogonadism
Hypogonadism occurs in approximately 50 % of acromegaly
patients, but is often reversible unless gonadotroph destruc-
tion has occurred (MQ) [36, 37]. Biochemical diagnosis in
males may be difficult, due to low sex hormone-binding
globulin levels (making interpretation of total testosterone
values more challenging) (LQ) [37]. In these circumstances,
assessment of clinical symptoms and bioavailable testoster-
one are important for diagnosis (DR) (Table 1). Concomitant
hyperprolactinemia should be considered as a cause of
hypogonadism (MQ). Treatment indications for hypogonad-
ism in acromegaly, and the specific therapy used, should be
similar to the non-acromegaly population (DR). In women,
hypogonadism should be assessed carefully and treated
appropriately, especially if fertility is desired (SR) [36].
Sleep apnea
Sleep apnea is currently under-assessed, and the prevalence is
high (up to 70 %) in newly diagnosed patients with acromegaly
(MQ) [22, 38, 39]. Therefore, every patient should have a
careful symptomatic assessment (e.g., by Epworth score), and
if necessary laboratory assessment, for sleep apnea at the time
of diagnosis, in collaboration with a respiratory physician (SR).
Despite successful acromegaly treatment, sleep apnea does
not consistently resolve (MQ), so post-treatment evaluation is
essential (SR) [22, 40–43]. Every effort should be made to
improve compliance with prescribed treatments including
continuous positive air pressure device and other devices (e.g.,
with appropriate measures tailored to patients with acro-
megaly, for example, specialized mouth pieces for use during
sleep). Consultation with maxillo-facial surgeons is advised,
and if necessary, elective surgery should be undertaken.
Other comorbidities and mortality
Quality of life
Quality of life (QoL) is an important outcome measure in
acromegaly [44]. Tools for measuring QoL in patients with
acromegaly (e.g., Acromegaly Quality of Life Question-
naire [AcroQoL]) are readily available and should be
considered in clinical practice (MQ) (Table 1) [44, 45].
QoL is impaired by GH-excess and GH-deficiency, and
therefore, when treating patients, it is important to recog-
nize induction of GH-deficiency, particularly in patients
who have undergone previous radiation therapy, as this can
have further deleterious effects on subsequent QoL and
other parameters (DR) [46].
Bones and joints
Arthropathy affects approximately 75 % of acromegaly
patients [47]. Any joint may be affected (large joints, small
joints and vertebrae), and range from osteoarthritis to
arthralgia to fractures (HQ) [48, 49]. Bony overgrowth and
soft-tissue swelling may also lead to nerve entrapment. Such
anatomical abnormalities may result in a delay to surgical
intervention for acromegaly (LQ). Disability due to acro-
megaly is probably under-estimated and can affect many
aspects of activities of daily living (MQ) [50–52]. Early
diagnosis of acromegaly is required to ensure early and
aggressive treatment to reduce arthropathy risk, because
joint and cartilage changes are irreversible (SR) [53, 54].
Vertebral fractures have been reported to occur in
acromegaly patients independently of bone mineral density
(BMD) (MQ) [49, 55–57]. Bone size may affect BMD
measurement, and the utility of dual-energy X-ray
absorptiometry for screening for abnormalities in the
absence of size correction is not well documented (LQ).
Thoracic and lumbar spine X-ray may be useful for diag-
nosing spinal deformities, particularly in symptomatic
patients (DR) (Table 1). Patients with acromegaly should
be evaluated for osteoporosis risk factors including vitamin
D deficiency, inadequate calcium intake, serum calcium to
assess hyperparathyroidism, glucocorticoid over-replace-
ment and hypogonadism (SR).
Colon polyps
Acromegaly is associated with increased colon polyps and
may be associated with increased risk of colorectal cancer,
but not cancer mortality (MQ) [58]. Colon length may
increase during acromegaly resulting in increased mucosal
folds (dolichocolon) (LQ) [59, 60]. It is recommended that
a screening colonoscopy be carried out at diagnosis in
adults (SR). If the colonoscopy is negative, then patients
should be screened similarly to the general population,
especially if insulin-like growth factor-I (IGF-I) levels are
normalized (DR) (Table 1) [59]. If IGF-I remains persis-
tently elevated, more frequent screening is recommended
(SR). If colonoscopy is abnormal, follow-up and screening
should be in accordance with clinical guidelines [59–61].
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Mortality
Uncontrolled acromegaly is associated with increased
mortality (HQ) [62, 63]. Co-existing adrenal insufficiency
and its therapy may have an impact on mortality (LQ). In
comparison with other forms of treatment aimed at con-
trolling GH hypersecretion, conventional radiation therapy
is specifically associated with increased overall mortality
(MQ) [20, 31, 64]. Radiation therapy increases risk of
hypopituitarism that leads to higher mortality; including
cerebrovascular disease (MQ) [64]. There is a need for
more data on mortality outcomes in patients receiving
stereotactic radiation therapy, which will become available
as more patients are followed-up in the long term.
Minimal dose of glucocorticoids required for efficacy in
hypopituitarism should be used, as over-replacement of glu-
cocorticoids can have a negative impact on mortality (LQ).
Attention to the GH status is important when using gluco-
corticoid replacement therapy because higher replacement
doses may be required when GH therapy is given (DR) [64].
Improved medical therapy is recommended to control
GH/IGF-I levels and improve mortality (SR) [31, 64, 65].
Gonadal, thyroid and GH deficiencies should also be
assessed and properly replaced, when indicated (SR).
Treatment outcomes in selected clinical conditions
Pregnancy
In women with acromegaly who wish to become pregnant,
pituitary function should be assessed and surgical or
medical treatment initiated as indicated (SR). There are
few data (animal or human) on the safety of pegvisomant in
pregnancy (VLQ) [66, 67].
Unless clinically indicated, pharmacological agents
should be discontinued on confirmation of pregnancy (SR).
In some pregnant women, IGF-I levels remain within the
normal range (for non-pregnant women), even in uncon-
trolled patients, and then increase after delivery. Bio-
chemical assessment of disease activity is of limited value
because of placental production of GH and IGF-I (LQ) [68,
69]. There is a need to encourage reporting of outcomes in
medically treated pregnant women with acromegaly.
Familial acromegaly
Familial acromegaly is generally diagnosed at an earlier age
than non-familial acromegaly [70], and young patients
(\30 years old) with aggressive acromegaly, or individuals
with a family member who has a pituitary tumor, should be
considered for genetic screening for markers of familial
acromegaly (DR). Carney complex, familial isolated pituitary
adenoma (FIPA) and multiple endocrine neoplasia type 1
should be considered (DR) [71]. An increased awareness that
FIPA is associated with mutations in the aryl hydrocarbon
receptor interacting protein (AIP) gene is required [70, 72–74].
Invasive macroadenomas
Access to multimodal treatment and involvement of a
multi-disciplinary team are needed in patients with inva-
sive macroadenomas (HQ). If visual fields are impaired,
immediate surgery is typically the first line therapy (HQ).
Pre-treatment with SRL may improve subsequent surgical
outcomes (MQ) [75–77]. Surgical debulking may improve
subsequent medical treatment outcomes (LQ) [78–80].
Radiation therapy may continue to have a place in the
acromegaly treatment algorithm (MQ) [81–84]. The choice
of treatment strategy should include consideration of
comorbidities, the projected length of time for hormone
normalization, therapy side-effects, pituitary function and
cost-benefit of the indicated strategy (DR).
Disease staging
Biochemical control
Over the past decade, biochemical criteria defining ‘con-
trol’ of disease activity have become increasingly rigorous
[4, 85]. The most recent definitions of active disease
(random GH C1 ng/ml; nadir GH after oral glucose toler-
ance test (OGTT) C0.4 ng/ml; and elevated IGF-I for age)
and optimal disease control (random GH \1 ng/ml when
treated with SRLs; nadir GH after OGTT\0.4 ng/ml after
surgery; and age-normalized IGF-I levels for all treatments
and as a unique parameter with pegvisomant usage) remain
valid (SR) [4, 86]. However, the definition for optimal
disease control comes with the caveat that assay-specific
normative data for post-OGTT nadir are required (DR).
Tumor control
The role of tumor characteristics and of optimal tumor growth
control has not been fully agreed by consensus. Factors pro-
posed to be associated with disease persistence after surgery
and/or a sub-optimal response to medical therapy include:
• Younger age at diagnosis (LQ) [87–89].
• High expression of tumor aggression markers like
Ki67, p53 and pituitary tumor transforming gene
(PTTG) (LQ) [90–93].
• Sparsely granulated adenomas [94] and hyper-intense
imaging on T2 weighted magnetic resonance imaging
(MQ) [94–98].
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• Very large adenomas and actively growing tumors
(MQ) [99–103].
• No previous radiation therapy, especially during peg-
visomant therapy (LQ) [6, 104–106].
• Previous, sub-optimal response to SRL therapy (LQ)
[107–112].
• High GH and IGF-I levels during long-term follow-up
(HQ) [102, 103, 107, 108, 110, 113–115].
• Larger tumor remnants after surgery (MQ) [114, 116].
The need for a staging tool?
A new model for describing overall patient assessment
before and during treatment would be valuable. The
rationale supporting the need for such a model is the
requirement to integrate a number of clinical metrics as
well as information on pituitary tumor characteristics with
the currently used biochemical markers. Ideally, such a
model should include data on:
• Clinical symptoms.
• Associated clinical signs and comorbidities.
• GH level.
• IGF-I level.
• Tumor size.
Conclusions
Effective management of acromegaly complications will
lead to decreased morbidity and mortality, and improved
QoL. Comprehensive multimodal acromegaly management
should integrate biochemical monitoring, careful assess-
ment of tumor behavior and clinical features, and
comorbidities.
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